Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction

Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordheim, Catherine Thieblemont, Denis Sahin, Christian Klein, Charles Dumontet

Mol Cancer Ther (2020) 19 (11): 2371–2381.

DOI: https://doi.org/10.1158/1535-7163.MCT-19-0839

Published: 03 November 2020

View article

Includes: Supplementary data

Journal Articles

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells

Matthieu Broussas, Nicolas Boute, Barbara Akla, Sven Berger, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Alain Beck, Jean-François Haeuw, Liliane Goetsch, Christian Bailly, Charles Dumontet, Thomas Matthes, Nathalie Corvaia, Christine Klinguer-Hamour

Mol Cancer Ther (2016) 15 (8): 1890–1899.

DOI: https://doi.org/10.1158/1535-7163.MCT-16-0041

Published: 03 August 2016

View article

Journal Articles

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies

Sébastien Cornet, Doriane Mathé, Kamel Chettab, Anne Evesque, Eva-Laure Matera, Olivier Trédan, Charles Dumontet

Mol Cancer Ther (2016) 15 (6): 1238–1247.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0759

Published: 02 June 2016

View article

Includes: Supplementary data

Journal Articles

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Mol Cancer Ther (2013) 12 (10): 2031–2042.

DOI: https://doi.org/10.1158/1535-7163.MCT-12-1182

Published: 07 October 2013

View article

Includes: Multimedia, Supplementary data

Journal Articles

Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells

Rouba Hage-Sleiman, Stéphanie Herveau, Eva-Laure Matera, Jean-Fabien Laurier, Charles Dumontet

Mol Cancer Ther (2011) 10 (2): 303–312.

DOI: https://doi.org/10.1158/1535-7163.MCT-10-0568

Published: 08 February 2011

View article

Includes: Supplementary data

Journal Articles

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein, Charles Dumontet

Mol Cancer Ther (2011) 10 (1): 178–185.

DOI: https://doi.org/10.1158/1535-7163.MCT-10-0385

Published: 10 January 2011

View article

Includes: Supplementary data

Journal Articles

Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA

Stéphane Vispé, Luc DeVries, Laurent Créancier, Jérome Besse, Sophie Bréand, David J. Hobson, Jesper Q. Svejstrup, Jean-Philippe Annereau, Didier Cussac, Charles Dumontet, Nicolas Guilbaud, Jean-Marc Barret, Christian Bailly

Mol Cancer Ther (2009) 8 (10): 2780–2790.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0549

Published: 12 October 2009

View article

Includes: Supplementary data

Journal Articles

Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

Charles Dumontet, Mary Ann Jordan, Francis F.Y. Lee

Mol Cancer Ther (2009) 8 (1): 17–25.

DOI: https://doi.org/10.1158/1535-7163.MCT-08-0986

Published: 12 January 2009

View article

Journal Articles

Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

Pascal Sève, John Mackey, Sylvie Isaac, Olivier Trédan, Pierre-Jean Souquet, Maurice Pérol, Raymond Lai, Alain Voloch, Charles Dumontet

Mol Cancer Ther (2005) 4 (12): 2001–2007.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0244

Published: 22 December 2005

View article

Journal Articles

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Lars Petter Jordheim, Olivier Guittet, Michel Lepoivre, Carlos M. Galmarini, Charles Dumontet

Mol Cancer Ther (2005) 4 (8): 1268–1276.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0121

Published: 10 August 2005

View article

NARROW

Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells

Pegfilgrastim Enhances the Antitumor Effect of Therapeutic Monoclonal Antibodies

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Silencing of Tubulin Binding Cofactor C Modifies Microtubule Dynamics and Cell Cycle Distribution and Enhances Sensitivity to Gemcitabine in Breast Cancer Cells

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA

Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies

Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only